Bromocriptine

證據等級: L5

預測適應症: 10 個

Bromocriptine: From Hyperprolactinemia to Schizophrenia (Negative Symptoms)

One-Sentence Summary

Bromocriptine is a dopamine D2/D3 receptor agonist, originally used for hyperprolactinemia, Parkinson’s disease, and type 2 diabetes management. The TxGNN model predicts it may be effective for Schizophrenia (specifically negative symptoms), with 3 clinical trials and 20 publications currently supporting this direction, making it the most evidence-rich prediction among 10 candidates.

Quick Overview

Item	Content
Original Indication	Hyperprolactinemia, Parkinson’s disease, acromegaly, type 2 diabetes (regulatory details pending)
Predicted New Indication	Schizophrenia (Rank 9 of 10; featured due to strongest evidence base)
TxGNN Prediction Score	99.73%
Evidence Level	L3 (observational studies & clinical investigations)
Malaysia Market Status	✓ Marketed
Number of Registrations	2
Recommended Decision	Hold

Note on Prediction Ranking: TxGNN ranked schizophrenia 9th out of 10 predictions. The top 8 predictions (ranks 1–8) are ultra-rare genetic/developmental disorders with L5 evidence (model prediction only, no clinical studies) and no identifiable mechanistic link. Schizophrenia is featured here because it is the only prediction with clinical trial and literature evidence. A summary of all 10 predictions is provided below.

All TxGNN Predicted Indications

Rank	Disease	TxGNN Score	Evidence Level	Trials	Publications	Recommendation
1	Congenital disorder of glycosylation with defective fucosylation	99.83%	L5	0	0	Hold
2	Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis	99.83%	L5	0	0	Hold
3	Retinal dystrophy with or without extraocular anomalies	99.82%	L5	0	15	Hold
4	Atypical glycine encephalopathy	99.82%	L5	0	0	Hold
5	Myopia 26, X-linked, female-limited	99.81%	L5	0	0	Hold
6	Hydranencephaly	99.80%	L5	0	1	Hold
7	Myopia X-linked	99.78%	L5	0	0	Hold
8	Charcot-Marie-Tooth disease, demyelinating, type 1G	99.78%	L5	0	0	Hold
9	Schizophrenia	99.73%	L3	3	20	Research Question
10	Syndromic myopia	99.73%	L5	0	0	Hold

Interpretation: Ranks 1–8 likely reflect TxGNN knowledge graph topology bias — rare disease nodes with low degree centrality can receive inflated scores without genuine biological rationale. Rank 9 (schizophrenia) and rank 3 (retinal dystrophy) are the only predictions with literature support.

Why is This Prediction Reasonable?

Bromocriptine is an ergot-derived dopamine D2/D3 receptor agonist and partial serotonin 5-HT2C agonist. Its primary therapeutic mechanism involves stimulation of dopamine D2 receptors in the tuberoinfundibular pathway (suppressing prolactin secretion), the nigrostriatal pathway (improving motor symptoms in Parkinson’s disease), and peripheral metabolic regulation (improving insulin sensitivity in type 2 diabetes).

The relationship between bromocriptine and schizophrenia is pharmacologically complex and somewhat paradoxical. The dopamine hypothesis of schizophrenia posits that mesolimbic D2 overactivity drives positive symptoms (hallucinations, delusions) — which is why all approved antipsychotics are D2 antagonists. However, mesocortical dopamine hypoactivity is believed to underlie negative symptoms (apathy, social withdrawal, cognitive deficits), which remain poorly addressed by current treatments. A low-dose D2 agonist could, in theory, preferentially stimulate presynaptic autoreceptors — paradoxically reducing dopamine release in the mesolimbic pathway while augmenting mesocortical transmission. Multiple clinical studies from the 1980s–1990s explored this “low-dose agonist” strategy with bromocriptine adjunctive to neuroleptics, with some evidence of improvement in negative symptoms (BPRS total scores improved ~29% in one study). More recent clinical interest focuses on bromocriptine’s role in managing antipsychotic-induced metabolic and endocrine side effects (hyperprolactinemia, prediabetes, weight gain), which are prevalent in schizophrenia patients.

That said, the safety concern is significant: bromocriptine can exacerbate or even induce psychotic symptoms. One published case report describes bromocriptine-induced schizophrenia in a previously non-psychotic patient. This dual-edged pharmacology — potentially helping negative symptoms while risking positive symptom exacerbation — makes this a legitimate research question rather than a straightforward repurposing candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03575000	Phase 4	Not yet recruiting	15	Open-label pilot evaluating bromocriptine as adjunct to antipsychotics for managing APD-associated prediabetes/insulin resistance in schizophrenia patients. Focuses on metabolic side effect management rather than psychiatric symptom treatment.
NCT00315081	Phase 3	Unknown	20	Bromocriptine for symptomatic risperidone-induced hyperprolactinemia in schizophrenic patients. Addresses a known indication (hyperprolactinemia) in a specific population. Endocrinological outcomes assessed.
NCT04181385	Phase 2/3	Unknown	15	Assessment of lipid response to acute olanzapine in healthy adults. Bromocriptine investigated as potential metabolic protective agent. Indirectly relevant — healthy volunteers, not schizophrenia patients.

Trial Evidence Summary: All three trials address bromocriptine’s role in managing metabolic/endocrine side effects of antipsychotic medications, not direct treatment of schizophrenia symptoms. No trial evaluates bromocriptine as a primary or adjunctive treatment for positive or negative symptoms of schizophrenia. Sample sizes are small (15–20 participants), and two trials have unknown completion status.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6574535	1983	Open-label trial	Psychiatry Research	Bromocriptine (1.25–40 mg) in 10 chronic schizophrenic patients; assessed symptomatology, sleep patterns, and prolactin response. One of the earliest clinical investigations.
2643996	1989	RCT (vs placebo)	Biological Psychiatry	Low-dose bromocriptine (2.5 mg/day) added to haloperidol: 29% BPRS improvement at 24h (vs 14% placebo, p<0.10). Acute improvement correlated negatively with plasma levels.
1679383	1991	Clinical study	Comprehensive Psychiatry	Bromocriptine for “negative” schizophrenia — explores dopamine agonist strategy based on mesocortical hypoactivity hypothesis. Open clinical trials of D2 agonist + neuroleptic combination.
8120934	1993	Case report	J Natl Med Assoc	Bromocriptine-induced schizophrenia: 53-year-old male developed schizophrenia 4 days after starting low-dose bromocriptine for macroprolactinoma. Resolved 5 days after discontinuation. Supports dopamine hypothesis.
8561400	1995	Clinical study	Ann Médico-Psychol	Neuroleptic–bromocriptine combination in 12 schizophrenic patients: 29% mean improvement in PANSS total score after 1 month. Suggests adjunctive utility.
18480682	2008	RCT (crossover)	J Clin Psychopharmacol	Randomized crossover comparing herbal medicine vs bromocriptine for risperidone-induced hyperprolactinemia. Bromocriptine used as active comparator for prolactin-lowering.
21157697	2011	Clinical observation	Pharmacopsychiatry	Disorganized schizophrenia did NOT deteriorate with dopamine agonists (cabergoline and bromocriptine) used for ablactation. Reassuring safety signal in stable patients.
26573387	2016	Case report	Nordic J Psychiatry	Bromocriptine mitigated paliperidone-induced metabolic/neurohormonal side effects AND improved negative symptoms in early-onset schizophrenia. Notable dual benefit.
31688399	2019	Systematic review & meta-analysis	J Clin Psychopharmacol	Prodopaminergic drugs for negative symptoms of schizophrenia — systematic review of RCTs. Addresses the broader therapeutic strategy that bromocriptine represents.
33571431	2021	Basic science	Cell	Cryo-EM structural insights into D1R and D2R signaling complexes. D2R identified as principal therapeutic target for schizophrenia; provides structural basis for understanding bromocriptine–D2R interaction.

Literature Summary: The evidence spans nearly 4 decades (1983–2024) and includes 2 small RCTs, multiple open-label trials, case reports, and systematic reviews. Key themes: (1) low-dose bromocriptine adjunctive to neuroleptics may improve negative symptoms (~29% BPRS improvement); (2) bromocriptine can induce or exacerbate psychosis; (3) most recent clinical interest focuses on managing antipsychotic metabolic/endocrine side effects. No large-scale definitive RCT exists for bromocriptine as a direct schizophrenia treatment.

Notable Secondary Finding: Retinal Dystrophy (Rank 3)

While most top-ranked predictions lack evidence, rank 3 (retinal dystrophy) includes one highly relevant publication:

PMID	Year	Type	Journal	Key Findings
39009597	2024	Pre-clinical / Drug repurposing	Nature Communications	Combination treatment (tamsulosin + metoprolol + bromocriptine) demonstrated mutation-agnostic efficacy in pre-clinical retinopathy models by suppressing intracellular cAMP and Ca²⁺ via GPCR modulation. Direct drug repurposing evidence for bromocriptine in inherited retinal disease.

This finding suggests an emerging research direction, though evidence remains pre-clinical (L4). The remaining 14 publications retrieved for this indication are tangentially related (covering extraocular anomalies, congenital ptosis, orbital pathology) and do not specifically address bromocriptine for retinal dystrophy.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Registration details pending)	—	—	—
(Registration details pending)	—	—	—

Bromocriptine has 2 registered products in Malaysia with market status “Marketed”. Specific registration numbers, product names, dosage forms, and approved indications were not available in the current data extract. Please consult the NPRA database for complete registration details.

Safety Considerations

Please refer to the package insert for safety information.

Known pharmacological safety concerns relevant to this repurposing evaluation:

Psychosis risk: Bromocriptine, as a dopamine D2 agonist, carries an inherent risk of inducing or exacerbating psychotic symptoms. At least one published case report documents bromocriptine-induced schizophrenia (PMID: 8120934). This is a critical concern for any schizophrenia-related repurposing.
Detailed warnings, contraindications, and drug interaction data were not available in the current evidence pack (classified as Blocking data gap DG001). Completion of safety profile review via NPRA package insert analysis is required before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: Bromocriptine has a well-documented pharmacological interaction with dopamine pathways relevant to schizophrenia, and a modest body of clinical literature (L3) supports its potential to improve negative symptoms when used adjunctively at low doses. However, the fundamental paradox — a D2 agonist for a disease treated by D2 antagonists — poses significant safety concerns, including the risk of psychotic exacerbation. The clinical trials identified focus on managing antipsychotic side effects (hyperprolactinemia, metabolic syndrome), not on treating core schizophrenia symptoms. The remaining 9 TxGNN predictions involve ultra-rare genetic disorders with no mechanistic rationale or clinical evidence, likely reflecting knowledge graph topology bias rather than genuine biological signals.

To proceed, the following is needed:

Complete safety profile review (NPRA package insert warnings, contraindications, DDI — currently a Blocking data gap)
DrugBank ID confirmation and detailed MOA documentation
Systematic review of all published adjunctive bromocriptine trials in schizophrenia, with focus on dose-response relationship and negative symptom outcomes
Assessment of whether modern atypical antipsychotics (with lower D2 occupancy) create a safer context for adjunctive D2 agonist therapy
For the retinal dystrophy prediction (rank 3): monitoring of clinical translation from the 2024 Nature Communications pre-clinical findings
Validation of TxGNN model predictions for rare disease indications (ranks 1–8) — recommend flagging as likely false positives due to low-degree node bias

Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. Data cutoff: 2026-04-09.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.